Clinical Trial: A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis

U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07890584) titled 'A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis' on Oct. 16.

Brief Summary: Approximately 56 participants who are 1 month old to 17 years old will be enrolled in this study. The total duration for this study will be 38 weeks (or up to 42 weeks when participants require a washout period due to prior exposure to prohibited medications) and includes the following periods:

* Active screening period of 6 weeks (or, up to 10 weeks for participants requiring a washout period).

* Treatment period of 28 weeks consisting of a 19-week dose titration period and 9-week s...